PHIL in the Treatment of Intracranial dAVF. (PHIL dAVF)
- Study HIC#:2000023267
- Last Updated:12/22/2022
Brief Summary:
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
- Age22 years - 80 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Lindsey Fraczkiewicz
- Phone Number: 1-203-785-3490
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Eligibility Criteria
Inclusion Criteria:
Age 22 - 80 years.
Subject is willing and capable of complying with all study protocol requirements, including specified follow-up period.
Subject or authorized legal representative must provide written informed consent prior to initiation of any study procedures.
Subject has an intracranial dAVF
Exclusion Criteria:
Subject having multiple dAVFs to be treated.
Subject with a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
Subject has known allergies to dimethylsulfoxide, iodine.
Subject is currently participating in another clinical study
Female subject is currently pregnant.
Subject has co-morbid conditions that may limit survival to less than 24 months.
